Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03277066 · ClinicalTrials.gov registry record · Phase 2

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

A Phase 2 study of Osteoarthritis of the Knee, sponsored by Noven Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
289
Enrollment target
1
Study location

NCT03277066 is a Phase 2 study of Osteoarthritis of the Knee that has completed, run by Noven Pharmaceuticals. The registered enrollment target is 289 participants, above the 202-participant average among 15 other Osteoarthritis of the Knee trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03277066, a Phase 2 study of Osteoarthritis of the Knee, has completed, sponsored by Noven Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
289 participants
Enrollment target
1
Study location

Study Summary

A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) of the Knee

Conditions Studied

Interventions

  • DRUG Placebo patch
  • DRUG Diclofenac Sodium Active Topical Patch 1
  • DRUG Diclofenac Sodium Active Topical Patch 2

Study Locations (1)

New Jersey

  • Noven Pharmaceuticals, Inc. - Jersey City

Trial Details

FieldValue
Enrollment Target 289 participants
Start Date 2017-09-07
Est. Completion 2019-09-25
Phase Phase 2

Sponsor

Noven Pharmaceuticals

5 total trials

What the Registry Record Tells You About NCT03277066

The ClinicalTrials.gov registry entry for NCT03277066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 15 other Osteoarthritis of the Knee trials with a reported enrollment target (43% higher). The listed sponsor is Noven Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis of the Knee appearing as the primary indexed condition, and to 3 interventions - of which Placebo patch is the first listed.

NCT03277066 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT03277066 about?

NCT03277066 is a clinical study titled "A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis". A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) of the Knee

What is the current status of trial NCT03277066?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2017-09-07. Estimated completion is 2019-09-25.

What conditions does trial NCT03277066 study?

This clinical trial studies the following conditions: Osteoarthritis of the Knee.

What interventions are being tested in trial NCT03277066?

The interventions under investigation include: Placebo patch (DRUG), Diclofenac Sodium Active Topical Patch 1 (DRUG), Diclofenac Sodium Active Topical Patch 2 (DRUG).

Who is sponsoring clinical trial NCT03277066?

This trial is sponsored by Noven Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03277066 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis of the Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.